A randomised, placebo-controlled, double-blind study of adjuvant Cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma
Primary Sponsor
Collaborating Groups
TROG Cancer Research
Accrual Target
412
Final Accrual
415
Closing Date of Accrual
20 August 2024
Trial Chairperson
Prof Sandro Porceddu - Princess Alexandra Hospital
Trial Contact
qa@trog.com.au
Related Post
24 September, 2025
Prostate Cancer Month: Focus on the TROG Genitourinary Working Party
To mark Prostate Cancer Month in September, we asked
24 September, 2025
TROG members and staff celebrate World Radiotherapy Awareness Day
LATEST NEWS: 24 September 2025 TROG Cancer Research staff